The Global Proton Therapy Market 2018-2022: Projected to Exceed a CAGR of 9% - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jan 23, 2019--The “Global Proton Therapy Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering.
The proton therapy market will register a CAGR of over 9% by 2022.
The incidence of many cancers such as lung cancer, breast cancer, prostate cancer, colorectal cancer, and stomach cancer is increasing globally.
The associated risk factors of cancers are also on the rise. A significant proportion of the risk of cancer incidence is attributed to the high body mass index, poor dietary habits lack of physical activity, tobacco use and alcohol consumption.
Advantages of proton therapy over standard radiation therapies
Protons can be charged to reach the exact depth where a tumor is located, then stop its further growth. Therefore, proton beams minimize exposure to the nearby healthy tissue surrounding the tumor.
High cost of proton bean therapy and lack of insurance coverage
The high capital costs of proton therapy facilities are restricting their adoption worldwide.
Key PlayersIBA Worldwide Hitachi Mevion Medical Systems ProTom International Sumitomo Corporation Varian Medical Systems
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
PART 05: MARKET SIZING
PART 06: FIVE FORCES ANALYSIS
PART 07: MARKET SEGMENTATION BY PRODUCTComparison by product Equipment Services Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: REGIONAL LANDSCAPERegional comparison Proton therapy market in Americas Proton therapy market in EMEA Proton therapy market in APAC Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
PART 12: MARKET TRENDSTechnological advances Increasing number of clinical trials for indication expansion
PART 13: VENDOR LANDSCAPE
PART 14: VENDOR ANALYSISVendors covered Vendor classification Market positioning of vendors IBA Worldwide Hitachi Mevion Medical Systems ProTom International Sumitomo Corporation Varian Medical Systems
For more information about this report visit https://www.researchandmarkets.com/research/5vbnj4/the_global_proton?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190123005602/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Nuclear Medicine and Radiopharmacology
INDUSTRY KEYWORD: HEALTH OTHER HEALTH GENERAL HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 01/23/2019 11:33 AM/DISC: 01/23/2019 11:33 AM